| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Research Abstract |
In this study, by comparing the physiochemical characteristics, stability as well as in vivo pharmacokinetics of different ZnPP micelles, we found that HPMA-ZnPP, with the particle size of about 80 nm, showed good stability in circulation, resulting in prolonged plasma half-life as well as tumor-selective accumulation (EPR effect). We thus selected HPMA-ZnPP for further development. In vitro studies using Hela cells exhibited a strong cytotoxicity of HPMA-ZnPP upon light irradiation. In vivo experiments showed an HPMA-ZnPP dose-dependent and irradiation dependent (intensity and duration) suppression of tumor growth. Moreover, the tumor-selective accumulation of HPMA-ZnPP was clearly detected in an in vivo imaging system. Token together, these findings strongly suggest the potential of HPMA-ZnPP as a new PDT drug for cancer, at the same time with tumor-detecting potency.
|
